BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Drozd Mariola (Medical University of Lublin, Poland), Szkultecka-Dębek Monika
Do We Need Real World Data? Polish ISPOR Chapter Therapeutic Programs, Pharmaceutical Care and Pharmaceutical Law Section (TPPCPL) Initial Discussion
Journal of Health Policy and Outcomes Research, 2014, nr 2, s. 94-99, rys., bibliogr. 22 poz.
Słowa kluczowe
Prawo farmaceutyczne, Informacja, Bazy danych
Pharmaceutical law, Information, Databases
Real world data can provide additional information in relation to medical treatments however there is a need to focus attention on methodology of data collection, data quality, potential sources of data and ensure proper legal environment for data collection. Unfortunately, despite large number of publications identified in PubMed database, there are only few available in a form of full text papers, the majority of publications are only abstracts from scientific conferences. In the future in order to share RWD experience it will be of benefit to encourage authors to work on full publications and not to limit their work only to abstracts(original abstract)
Pełny tekst
  1. Garrison L. et al. Using RWD for coverage and payment decisions: ISPOR RWD Task Force Report, Value in Health, 2007, 10, 5
  2. Masters E. T. et al. Real World Data for Use in the Real World: The Pain Paradigm, ISPOR Connections, vol. 19, Nr2, March/April 2013
  3. Zhang F. et al. Real-world use of the second-generation cobalt-chromium sirolimus-eluting stents: 12-month results from the prospective multicentre FOCUS registry. FOCUS registry investigators. EuroIntervention. 2012 Dec 20; 8(8):896-903. doi: 10.4244/EIJV8I8A138
  4. Xu B. et al. Comparison of long-term clinical outcome after successful implantation of FIREBIRD and CYPHER sirolimus-eluting stents in daily clinical practice: analysis of a large single-center registry.; Chin Med J (Engl). 2011 Apr; 124(7): 990-6
  5. Rosenman M.B. et al. Perceived or actual barriers to warfarin use in atrial fibrillation based on electronic medical records. Am J Ther. 2012 Sep; 19(5): 330-7; doi: 10.1097/MJT.0b013e3182546840
  6. Zimmerman M. et al. Determining remission from depression on two self-report symptom scales: a comparison of the Quick Inventory of Depressive Symptomatology and the Clinically Useful Depression Outcome Scale. Comprehensive Psychiatry 2013, 53, 7, p. 901-10488. ​Available from: (
  7. Wise E. A. Statistical significance testing and clinical effectiveness studies. Psychotherapy (Chic). 2011 Sep; 48(3): 225-8; discussion 234-6; doi: 10.1037/a0022701
  8. Leproust S. et al. PDB18 - Treatment Maintenance Duration of Dual Therapy with Metformin and Sitagliptin in Type 2 Diabetes - Real-World Data From Odyssee Study, Value in Health, 2014, 17, 7, p. A334-A335; ​Available from: (
  9. Iwasaki K. et al. PDB20 - Example Of Analysis Utilizing Real World Data: Medical Cost Reduction By Advising Untreated-Diabetes Patients To Visit Doctors, Value in Health, 2014, 17, 7, p. A744; ​Available from:; (
  10. Iwasaki K. et al. PCV25 - Example of Analysis Utilizing Real World Data: Medical Cost Reduction by Advising Untreated-Hypertension Patients to Visit Doctors, Value in Health, 2014, 17,7,p. A760; ​Available from:;(
  11. Iwasaki K. et al. DU2 - Example of Analysis Utilizing Real World Data: Medical Cost Reduction of Combination Drugs, Value in Health, 2014, 17, 7, p. A720-A721; ​Available from:; (
  12. Baser O. et al. PMS3 - Impact of Comorbidity Burden on Real-World Health Care Costs of Rheumatoid Arthritis Patients in Turkey, Value in Health, 2013, 16, 7, p. A555; ​Available from:; (
  13. De Rosa M. et al. PHP36 - Monitoring Health Processes in the Real World: An Italian Population Database Experience, Value in Health, 2013, 16, 7, p. A677; ​Available from:; (
  14. Danchin N. et al. Prise en charge cardiovasculaire en prévention primaire : le monde réel, Archives of Cardiovascular Diseases Supplements, 2012, 4, 4, p. 279-283; ​Available from:; (
  15. Jenkins D. et al. PRM188 - Evaluation of Methods for the Inclusion of Real World Evidence in Network Meta-Analysis - A Case Study in Multiple Sclerosis, Value in Health, 2014, 17, 7, p. A576; ​Available from:; (
  16. Gemmen E. et al. PRM153 - Practical approaches to achieving real-world study data representative of the target population, Value in Health, 2014, 17, 3 p. A207; ​Available from:; (
  17. Mussolino F. et al. PCV121 - Real world data: a tool for decision making in health care, Value in Health, 2014, 17, 3, p. A123; ​Available from:; (
  18. Clark O.A.C. et al. PCN39 - Budgetary Impact of Oral Chemotherapy in Brazil: A Real World Data Analysis From The Private Payers' Perspective, Value in Health, 2014, 17, 3, p. A74; ​Available from:; (
  19. Purwins S. et al. PSS54 - Health Related Quality of Life-Outcome in National Care - Real World Data from the German Psoriasis-Registry "Psobest", Value in Health, 2013, 16, 7, p. A511; ​Available from:; (
  20. Rizvi S.J. et al. Treatment-resistant depression in primary care across Canada Can J Psychiatry 2014,59,7: 349-57
  21. Katodritou E. et al. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann Hematol. 2014, 93, 1: 129-39; doi: 10.1007/s00277-013-1841-y
  22. Roche N. et al. Quality Standards for Real-World Research. Focus on Observational Database Studies of Comparative Effectiveness. Annals of the American Thoracic Society, 2014, 11, Supplement 2: S99-S104; doi: 10.1513/AnnalsATS.201309-300RM
Cytowane przez
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu